WAIVER UNDER THE SECURITIES PURCHASE AGREEMENT DATED OCTOBER 23, 2023Waiver Under the Securities Purchase Agreement • February 14th, 2024 • Ensysce Biosciences, Inc. • Pharmaceutical preparations
This Waiver under the Securities Purchase Agreement dated October 23, 2023 (this “Waiver”) is entered into effective as of this 12th day of February 2024 (the “Effective Date”) by and among Ensysce Biosciences, Inc., a Delaware corporation (the “Company”) and each purchaser under the Securities Purchase Agreement, as defined below (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”), whose signatures are set forth on the signature pages hereto. Capitalized terms not otherwise defined in this Waiver shall have the meanings given to them in the Securities Purchase Agreement, dated as of October 23, 2023 (the “Securities Purchase Agreement”), by and among the Company and the Purchasers.
